Nuvilex Inc. (NASDAQ:PMCB) Sees Large Increase in Short Interest

Nuvilex Inc. (NASDAQ:PMCB) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 469,898 shares, a growth of 356.3% from the April 30th total of 102,979 shares. Approximately 4.9% of the company’s stock are short sold. Based on an average daily volume of 382,797 shares, the short-interest ratio is currently 1.2 days.

Nuvilex Stock Performance

NASDAQ PMCB opened at $0.86 on Friday. The company has a market capitalization of $9.21 million, a price-to-earnings ratio of -0.77 and a beta of 0.46. The company’s 50-day simple moving average is $0.74 and its two-hundred day simple moving average is $0.78. Nuvilex has a one year low of $0.63 and a one year high of $1.51.

Analysts Set New Price Targets

A number of research firms have commented on PMCB. Wall Street Zen raised shares of Nuvilex to a “sell” rating in a research report on Saturday, January 31st. Weiss Ratings reissued a “sell (d)” rating on shares of Nuvilex in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Nuvilex Company Profile

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte.